SELLAS Life Sciences Receives Fast Track Designation from
- SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response (ORR) in r/r Peripheral T-cell Lymphomas (PTCL); ORR in r/r PTCL...
Source: globenewswire.com
Stay updated with breaking news from Track Designation Accelerates. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response (ORR) in r/r Peripheral T-cell Lymphomas (PTCL); ORR in r/r PTCL...